PRESS RELEASE published on 08/15/2023 at 07:25, 2 years 5 months ago Spexis announces USD $2.5 million capital commitment to support the upcoming Phase 3 ColiFin® studies
PRESS RELEASE published on 07/18/2023 at 12:26, 2 years 6 months ago Original-Research: Spexis AG (von First Berlin Equity Research GmbH): Buy
PRESS RELEASE published on 06/30/2023 at 07:15, 2 years 7 months ago Spexis announces engagement with Maxim Group LLC as M&A advisor to support evaluation of strategic transactions
PRESS RELEASE published on 06/26/2023 at 17:31, 2 years 7 months ago Spexis announces the results of its Annual General Meeting 2023
PRESS RELEASE published on 06/07/2023 at 07:30, 2 years 7 months ago Spexis announces the publication of promising results for a novel class of macrocyclic, peptidomimetic antibiotics in Science Advances
PRESS RELEASE published on 05/30/2023 at 07:15, 2 years 8 months ago Spexis provides business update and announces financial results for the full year 2022
PRESS RELEASE published on 04/28/2023 at 07:20, 2 years 9 months ago Spexis has received temporary approval of an extension until 31 of May 2023 for the disclosure obligation in connection with the publication and the filing of the annual report 2022.
PRESS RELEASE published on 04/18/2023 at 07:15, 2 years 9 months ago Spexis announces closing of capital commitment of USD 4.5 million from SPRIM Global Investments (SGI) to enable initiation of ColiFin® Phase 3 study
PRESS RELEASE published on 02/08/2023 at 07:20, 2 years 11 months ago Spexis and SPRIM Global Investments (SGI) Announce Plans for Clinical Trial Partnership to Fund up to Half of the Projected Phase 3 Clinical Development Costs of ColiFin®
PRESS RELEASE published on 01/25/2023 at 12:56, 3 years ago Original-Research: Spexis AG (von First Berlin Equity Research GmbH): Buy
Published on 02/05/2026 at 15:10, 12 minutes ago Electric Metals (USA) Limited Announces Change of Auditor
Published on 02/05/2026 at 14:50, 32 minutes ago High Tide Resources Announces Non-Brokered Private Placements
Published on 02/05/2026 at 14:30, 52 minutes ago Electrovaya Announces Date for Q1-2026 Financial Results & Conference Call
Published on 02/05/2026 at 14:30, 52 minutes ago Innodata to Report Fourth Quarter and Fiscal Year 2025 Results
Published on 02/05/2026 at 14:00, 1 hour 22 minutes ago Organto Foods Inc. Expects Strong 2026 Growth Driven by Retail Wins and Expanded Supply Partnerships
Published on 02/05/2026 at 15:15, 7 minutes ago FIS SUCCESSFULLY COMPLETES €770 MILLION BOND ISSUANCE
Published on 02/05/2026 at 15:12, 10 minutes ago Form 8.3 - The Vanguard Group, Inc.: Avadel Pharmaceuticals plc
Published on 02/05/2026 at 11:30, 3 hours 52 minutes ago Déclaration nombre d'actions et droits de vote - 05.02.2026
Published on 02/05/2026 at 11:30, 3 hours 52 minutes ago Disclosure of shares outstanding and voting rights - 05.02.2026
Published on 02/04/2026 at 18:04, 21 hours 18 minutes ago Capital et droits de vote au 31 janvier 2026
Published on 02/04/2026 at 18:04, 21 hours 18 minutes ago Total number of voting rights and shares making up the share capital at January 31, 2026
Published on 02/04/2026 at 17:45, 21 hours 37 minutes ago Information concerning the total number of voting rights and shares 2026 01 31
